基于体素的剂量学可预测接受90Y玻璃微球放射性栓塞治疗的肝细胞癌患者的肝毒性
该回顾性分析纳入176例接受放射性栓塞的肝细胞癌患者(78例部分肝治疗、98例全肝治疗),比较基于体素与多室剂量学参数对治疗后6个月胆红素3级及以上升高的预测能力。结果显示V20、V30、V40的曲线下面积分别为0.77、0.78、0.79,优于全非肿瘤肝组织平均吸收剂量(AD-WNTLT)的0.67;全肝治疗亚组中V40曲线下面积达0.84,V30阈值为78%、V40为72%、AD-30为43 Gy。作者认为基于体素的剂量学可能更准确预测肝毒性,但需进一步研究验证。
要点
- V20、V30、V40预测胆红素3级及以上升高的曲线下面积分别为0.77、0.78、0.79,优于AD-WNTLT的0.67。
- 全肝治疗亚组中V40曲线下面积为0.84,V30为0.82,AD-30为0.82,AD-WNTLT为0.63。
- V30阈值78%、V40阈值72%、AD-30阈值43 Gy,部分肝治疗亚组未达统计学显著。
核心结论
- 在肝细胞癌放射性栓塞患者中,基于体素的剂量学可能比多室剂量学更准确预测肝毒性,或有助于通过剂量上调或下调来优化治疗反应。
- 结果提示V40为72%在全肝治疗中可能特别有用,但需进一步研究验证这些结果。
研究设计与样本
- 回顾性分析纳入176例肝细胞癌患者,其中78例接受部分肝治疗、98例接受全肝治疗。
- 利用治疗前99mTc标记人血清白蛋白SPECT及增强CT/MRI进行基于体素和多室剂量学计算。
- 治疗后胆红素变化按常见不良事件评价标准分级,分析治疗后6个月肝毒性,采用受试者工作特征曲线下面积评价预测能力,阈值通过约登指数确定。
主要发现
- 预测治疗后胆红素3级及以上升高的曲线下面积:V20为0.77、V30为0.78、V40为0.79,AD-WNTLT为0.67。
- 全肝治疗亚组中,V20曲线下面积0.80、V30为0.82、V40为0.84、AD-20为0.80、AD-30为0.82,AD-WNTLT为0.63。
- V20(P=0.03)、V30(P=0.009)、V40(P=0.004)、AD-20(P=0.04)、AD-30(P=0.02)的准确度优于AD-WNTLT,但彼此之间无显著差异。
- 相应阈值为V30 78%、V40 72%、AD-30 43 Gy;部分肝治疗亚组未达统计学显著。
关键数值与推荐
- V20、V30、V40分别指非肿瘤肝组织接受至少20 Gy、至少30 Gy、至少40 Gy照射的体积。
- AD-20、AD-30分别指非肿瘤肝组织中吸收剂量最低的20%、30%体积所对应的阈值吸收剂量。
- AD-WNTLT指全非肿瘤肝组织的平均吸收剂量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究以验证这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Personalized dosimetry holds promise to improve radioembolization treatment outcomes in hepatocellular carcinoma (HCC) patients. To this end, tolerance absorbed doses for nontumor liver tissue are assessed by calculating the mean absorbed dose to the whole nontumor liver tissue (AD-WNTLT), which may be limited by its neglect of nonuniform dose distribution. Thus, we analyzed whether voxel-based dosimetry could be more accurate in predicting hepatotoxicity in HCC patients undergoing radioembolization. Methods: In total, 176 HCC patients were available for this retrospective analysis; of these, 78 underwent partial- and 98 whole-liver treatment. Posttherapeutic changes in bilirubin were graded using the Common Terminology Criteria for Adverse Events. We performed voxel-based and multicompartment dosimetry using pretherapeutic 99mTc-labeled human serum albumin SPECT and contrast-enhanced CT/MRI and defined the following dosimetry parameters: AD-WNTLT; the nontumor liver tissue volume exposed to at least 20 Gy (V20), at least 30 Gy (V30), and at least 40 Gy (V40); and the threshold absorbed dose to the 20% (AD-20) and 30% (AD-30) of nontumor liver tissue with the lowest absorbed dose. Their impact on hepatotoxicity after 6 mo was analyzed using the area under the receiver-operating-characteristic curve; thresholds were identified using the Youden index. Results: The area under the curve for prediction of posttherapeutic grade 3+ increases in bilirubin was acceptable for V20 (0.77), V30 (0.78), and V40 (0.79), whereas it was low for AD-WNTLT (0.67). The predictive value could further be increased in the subanalysis of patients with whole-liver treatment, where a good discriminatory power was found for V20 (0.80), V30 (0.82), V40 (0.84), AD-20 (0.80), and AD-30 (0.82) and an acceptable discriminatory power was found for AD-WNTLT (0.63). The accuracies of V20 (P = 0.03), V30 (P = 0.009), V40 (P = 0.004), AD-20 (P = 0.04), and AD-30 (P = 0.02) were superior to that of AD-WNTLT but did not differ significantly from each other. The respective thresholds were 78% (V30), 72% (V40), and 43 Gy (AD-30). Statistical significance was not reached for partial-liver treatment. Conclusion: Voxel-based dosimetry may more accurately predict hepatotoxicity than multicompartment dosimetry in HCC patients undergoing radioembolization, which could enable dose escalation or deescalation with the intent to optimize treatment response. Our results indicate that a V40 of 72% may be particularly useful in whole-liver treatment. However, further research is warranted to validate these results.
引用
- Watanabe M, Grafe H, Theysohn J, et al. Voxel-Based Dosimetry Predicts Hepatotoxicity in Hepatocellular Carcinoma Patients Undergoing Radioembolization with 90Y Glass Microspheres. J Nucl Med. 2023. PMID: 37290792. doi:10.2967/jnumed.122.264996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。